David McDonnell

Statistics

Publications

Citations

1.7K

H-Index

Active since

2007

Affiliations

Eli Lilly (United States)(Current)

Alkermes (United States)

Alkermes (Ireland)

Zucker Hillside Hospital

Eli Lilly (United Kingdom)

David McDonnell is an author at Eli Lilly (United States) specializing in antipsychotic therapy, antipsychotic pharmacotherapy, and clinical pharmacology.

ORCID

Publications per year

2007–2023

Publications

Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia

John M. Kane, Holland C. Detke, Dieter Naber et al. · American Journal of Psychiatry · 2009 · 197 citations

Pharmacy, Pharmacotherapy, Psychiatry +16

Dose correspondence between olanzapine long-acting injection and oral olanzapine

Holland C. Detke, Fangyi Zhao, Parag Garhyan et al. · International Clinical Psychopharmacology · 2010 · 185 citations

Pharmacy, Pharmacotherapy, Psychiatry +17

Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression

Mauricio Tohen, David McDonnell, Michael Case et al. · The British Journal of Psychiatry · 2012 · 128 citations · Full text

Pharmacy, Pharmacotherapy, Psychiatry +17

An 8-Week, Double-Blind, Randomized, Placebo-Controlled Study of Olanzapine Long-Acting Injection in Acutely Ill Patients With Schizophrenia

John Lauriello, Tim Lambert, Scott W. Andersen et al. · The Journal of Clinical Psychiatry · 2008 · 119 citations

Pharmacy, Pharmacotherapy, Psychiatry +17

Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study

Christoph U. Correll, John W. Newcomer, Bernard L. Silverman et al. · American Journal of Psychiatry · 2020 · 119 citations

Pharmacy, Pharmacotherapy, Psychiatry +16

1–5 of 35